

Angiogenesis in Human Development

Jan Kitajewski

ICRC 916, ph 851-4688, email: jkk9

BACKGROUND READING:

Vascular Development

"Signaling Vascular Morphogenesis and Maintenance"
Douglas Hanahan. *Science* 277: 48-50. in Perspectives. (1997)

VEGF Signaling

"VEGF Receptor Signaling – in control of vascular function"
Ollsson, Dimburg, Krueger, and Lena Claesson-Welsh. *Nat. Rev. Mol. Cell Biol.* 7: 359-71 (2006)

Notch and arterial specification

"Arterial Venous Specification During Development"
Matthew Swift and Brant M. Weinstein. *Circ. Res.* 104: 576-588 (2009)

Lymphatic Development



"Lymphatic Vascular Development"
Guillermo Oliver. *Nature Rev Immunology* 4: 35-45 (2004)


Wnts and retinal angiogenesis


"Wnt/Frizzled Signaling in the Vasculature: New Angiogenic Factors in Sight"
Nestor Masckauchan and Jan Kitajewski. *Physiology* 21: 181-188 (2006)

Vascular Development

- **Vasculogenesis** = de novo tube formation
- **Angiogenesis** = sprouting of new tubes off of pre-existing tubes
- Cell types
 - Endothelial Cell = cell type that makes up and lines blood vessels
 - Mural Cells** = specialized cells that surround blood vessels
 - Pericytes
 - Smooth muscle cells
- **Angiogenic Factors**
 - Vascular Endothelial Growth Factor (VEGF-A, VEGF-B, PlGF, VEGF-C.....)
 - Angiopoietins (Ang 1, Ang2,)
 - Notch ligands (Jagged1, Delta4)







pericyte

*Endothelial
cell*

***Lymphatic
vessel***

***blood
vessel***







Figure 13.31 *The Biology of Cancer* (© Garland Science 2007)



Vasculogenesis



Specification of
endothelial precursor
cells (EPCs)

EPCs (dividing and
differentiating into
endothelial cells)


Vasculogenic cord

Schoenwolf et al: Larsen's Human Embryology, 4th Edition.

Vascular Development

VASCULOGENESIS

Angiogenesis



Schoenwolf et al: Larsen's Human Embryology, 4th Edition.

Vascular Development

ANGIOGENESIS


Vascular Development

ANGIOGENESIS


Cellular steps in Angiogenesis


- 1) Biochemical Response and Preparation
- 2) Sprout initiation
- 3) Migration
- 4) Proliferation
- 5) Survival
- 6) Tube Formation
- 7) Maturation
- 8) Completion
- 9) Blood Flow

Angiogenesis - Basement Membrane Breakdown




Angiogenesis - Endothelial Cell Migration







Angiogenesis - Endothelial Cell Proliferation





Angiogenesis - Capillary Morphogenesis






Angiogenesis - Vascular Maturation






Angiogenesis - Vascular Maturation



VEGF and VEGF Receptors




VEGF = VEGF-A

angiogenic factor


VEGF Receptor-2

endothelial-specific signaling receptor




VEGF-B and PlGF VEGF Receptor-1

specialized angiogenic factor
endothelial specific signaling




VEGF-C and VEGF-D lymphangiogenic factor

VEGF Receptor-3 lymphatic endothelial specific signaling






VEGF-receptor signaling


Promotes:
Proliferation
Migration
Survival



VEGF is a hypoxia induced gene

Mechanism for producing angiogenic factor in conditions of low tissue oxygen





Hypoxia-induced angiogenesis

Hyperoxia-induced pruning

Vessel maturation


Vegf as an angiogenic factor


Vegf as a survival factor

Vegf refractoriness

Schoenwolf et al: Larsen's Human Embryology, 4th Edition.

Copyright © 2008 by Churchill Livingstone, an imprint of Elsevier, Inc. All rights reserved






Notch drives cell fate determination

Notch/Notch ligand interaction:



- mechanism for setting and maintaining state of differentiation
- fates locked in via lateral inhibition




Notch drives cell fate differentiation

Notch/Notch ligand interaction:


- mechanism for driving state of differentiation
- fates locked in via lateral inhibition





Notch drives cell fate differentiation







Notch drives cell fate differentiation








Notch restricts endothelial sprouting through feedback to VEGF signaling





Endothelial Specification






Schoenwolf et al: Larsen's Human Embryology, 4th Edition.
 Copyright © 2008 by Churchill Livingstone, an imprint of Elsevier, Inc. All rights reserved

Vascular Specification

Vessels specialization during development



- 1) Arterial-Venous Vessels
- 2) Lymphatic Vessels
- 3) Tissue specific vessels

Notch drives cell fate differentiation




Notch promotes arterial specification

a




A molecular pathway for arterial-venous fate determination




Swift, M. R. et al. Circ Res 2009;104:576-588

a




VEGF and VEGF Receptors






Cardinal vein

Competency
(*Vegfr3⁺/Lyve1⁺*)



Budding of
lymphatic EC

Specification
(*Prox1⁺*)



Formation of
lymph sacs



Lymphatic differentiation
(*Podoplanin⁺/Nrp2⁺*)




Sprouting of lymphatic
vessels to periphery



Schoenwolf et al: Larsen's Human Embryology, 4th Edition.
Copyright © 2008 by Churchill Livingstone, an imprint of Elsevier, Inc. All rights reserved

slp76^{-/-} E14.5




Sabin 1901




Structure of blood and lymphatic vasculature in dermis



normal



+ lymphatics





- lymphatics




Mouse with mutation in VEGFR-3

Figure 2 **Blood and lymphatic vessels in mouse ear.** a, Whole mount immunohistochemical staining of lymphatic vessels (LYVE-1; red) and blood vessels (PECAM-1; green) in mouse ear. b, Transgenic overexpression of the VEGF-C mutant C156S in the skin leads to enlargement of the lymphatic vessels, whereas only a few lymphatic ECs are present in the ear of a Chy lymphoedema mouse¹² (c). We thank G. Thurston for the stainings and D. Jackson for the LYVE-1 antibodies.











fovea →

← optic
nerve

Human retina




Normal intraretinal vasculature



Fig. 25. A view of the fundus of the eye and of the retina in a patient who has advanced diabetic retinopathy.

Retinopathy of Prematurity



Retinopathy of Prematurity

L.E.H. Smith / *Growth Hormone & IGF Research* 14 (2004) S140–S144




Fig. 1. Mechanism for retinopathy of prematurity (ROP) (Reprinted, with permission, from [37]).




FEVR- Familial Exudative Vitreoretinopathy

- First described by Criswick and Schepens [Am. J. Ophthalmol. 68: 578-594 (1969)]
- Autosomal dominant, recessive, and X-linked forms; variable phenotype
- Clinical characteristics
 - mild to severe vision loss
 - retina: avascular peripheral retina, exudates, neovascularization, fibrovascular masses, traction or rhegmatogenous retinal detachment
 - vitreous: posterior vitreous detachment, fibrovascular membranes, hemorrhage
 - other: cataract, neovascular glaucoma


Retinal defects in FEVR patients heterozygous for Fz4 M157V

Normal

hFz4(+/-)




Frizzled-4 is a Wnt receptor



Intraocular hemorrhage in Fz4(-/-) mice

WT

-/-





Absence of intra-retinal capillaries in Fz4(-/-) mice

WT

-/-

Outer IPL




Norrie Disease


- First described by Norrie (1927) and analyzed systematically by Mette Warburg [Acta Ophthalmologica 39: 757-772 (1961); 41: 134-146 (1963); 89: 1-147 (1966)]
- X-linked recessive with variable phenotype
- Clinical characteristics
 - moderate vision loss to congenital blindness
 - retina: retinal folding and detachment, retinal degeneration, fibrovascular masses, vitreoretinal hemorrhage
 - vitreous: persistent primary vitreous
 - other: progressive sensorineural deafness

Figure 1. The Norrin protein.

Missense and nonsense mutations in Norrin leading to classic or mild Norrie disease (ND) and to FEVR. Amino acid numbering is given on the scale below the protein. LP, leader peptide; CRD, cysteine-rich domain. The CRD is homologous to domains in the proteins indicated below (adapted from [1]).



Norrin is a ligand for Frizzled-4



Molecular genetics of Norrie Disease and FEVR

- FEVR

One autosomal dominant FEVR gene identified by Robitaille et al [Nature Genetics 32: 326-330 (2002)] encodes Frizzled4, a putative Wnt receptor. A second autosomal dominant FEVR locus encodes the Wnt co-receptor Lrp5 [Toomes et al [IOVS 45: 2083-2090 (2004)]; Jiao et al [Am J Hum Genet 75: 878-884 (2004)].

- Norrie disease

Gene identified by Berger et al and Chen et al [Nature Genetics 1: 199-203 and 204-208 (1992)]

The encoded protein is small (133 amino acids in length), has the same pattern of cysteines as seen in transforming growth factor beta, and begins with a signal sequence (i.e. it looks like a secreted protein). No known biochemical function.

Vessel component to human diseases

- Tumor angiogenesis *(treatment available ?)*
- Tumor lymphangiogenesis, metastasis
- Diabetic vascular complication
 - Diabetic retinopathy
 - Stroke
 - Ischemia
 - Wound repair
- Heart disease
 - Occluded vessels
 - Rebuilding vessels of damaged heart tissue
- Obesity
- Lymphedema
- Blindness
 - Wet Macular Degeneration *(treatment available)*
 - Retinopathy of Prematurity

